Predicting adverse events of cancer medicines: a secondary analysis of clinical trial data
- In: Poster Presentation
- At: Stockholm (Sweden) (2017)
- Type: Poster
- Poster code: P-E-033-Monday
- By: SORICH, Michael (Flinders University, Adelaide, Australia)
- Co-author(s): Michael Sorich: Clinical Pharmacology, Flinders University, Adelaide, Australia
Andrew Rowland: Clinical Pharmacology, Flinders University, Adelaide, Australia
Ganessan Kichenadasse: Flinders Centre for Innovation in Cancer, Flinders University, Adelaide, Australia
Richard Woodman: Flinders Centre for Epidemiology and Biostatistics, Flinders University, Adelaide, Australia
Arduino Mangoni: Clinical Pharmacology, Flinders University, Adelaide, Australia - Abstract:
Backgrounds
Secondary analysis of pooled clinical trial data is an important means of identifying patient characteristics and laboratory/biological markers that predict individuals at greatest risk of toxicities from cancer medicines.Aims
To evaluate risk factors for proteinuria in patients with metastatic renal cell carcinoma (mRCC) treated with a .. The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress.
Please login
Last update 28 September 2023